Thus, the suppressive effect of GBM-N019 on mTOR, CDK6, and STAT3 signaling pathways could be of translational relevance to the immunogenicity status of GBM patients, and this issue is currently under vigorous investigation. The gene discussed is CDK6; the disease is glioblastoma.